Cosciens Biopharma Inc (CSCI)

Dec 23, 2024

COSCIENS Biopharma halts investment in macimorelin; CMO to depart - Seeking Alpha

Dec 23, 2024

Dec 23, 2024

COSCIENS Biopharma Focuses on Natural Product Growth - TipRanks

Dec 23, 2024

Dec 23, 2024

Cosciens Biopharma provides update, reiterates pipeline prioritization - TipRanks

Dec 23, 2024

Dec 23, 2024

Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail

Dec 23, 2024

Dec 23, 2024

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewswire

Dec 23, 2024

Dec 23, 2024

COSCIENS Biopharma Discontinues Key Drug Trial, Pivots to Natural Products Pipeline - StockTitan

Dec 23, 2024

Dec 20, 2024

CSCI stock touches 52-week low at $2.61 amid market challenges - Investing.com Australia

Dec 20, 2024

Dec 20, 2024

CSCI stock touches 52-week low at $2.61 amid market challenges By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 16, 2024

COSCIENS Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 16, 2024

Dec 05, 2024

This Biopharma Stock Could Be 2025’s Biggest Comeback Story - Wealth Awesome

Dec 05, 2024

Dec 02, 2024

Aeterna Zentaris : to Present at Upcoming Biotech Showcase Conference in San Francisco - Marketscreener.com

Dec 02, 2024

Nov 22, 2024

CSCI stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada

Nov 22, 2024

Nov 22, 2024

CSCI stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 15, 2024

Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn

Nov 15, 2024

Nov 15, 2024

COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

COSCIENS Biopharma: Q3 Earnings Snapshot - The Pioneer

Nov 13, 2024

Nov 12, 2024

COSCIENS Biopharma Advances Merger and Pipeline - TipRanks

Nov 12, 2024

Nov 12, 2024

Shimmick Announces New CEO - The Manila Times

Nov 12, 2024

Nov 12, 2024

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

COSCIENS Q3 Loss Widens to $5.8M, Discontinues Key Programs Amid Pipeline Shift | CSCI Stock News - StockTitan

Nov 12, 2024

Nov 07, 2024

CSCI stock touches 52-week low at $3.4 amid market fluctuations - Investing.com India

Nov 07, 2024

Nov 04, 2024

Hypoparathyroidism Market to Grow by USD 474.9 Million from 2024-2028, Driven by Thyroid Treatment Awareness Programs and AI-Powered Market InsightsTechnavio - PR Newswire

Nov 04, 2024

Nov 03, 2024

Cosciens Biopharma (TSX:CSCI) EPS without NRI : C$-4.32 (TTM As of Jun. 2024) - GuruFocus.com

Nov 03, 2024

Oct 30, 2024

AEterna Zentaris : March 10, 2015 Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015 - Marketscreener.com

Oct 30, 2024

Oct 24, 2024

Yorvipath-finders? Septerna, others forge on in hypothyroidism - BioWorld Online

Oct 24, 2024

Oct 17, 2024

Cosciens Biopharma (FRA:ET8) Enterprise Value : €-13.18 Mil (As of Oct. 17, 2024) - GuruFocus.com

Oct 17, 2024

Oct 17, 2024

Cosciens Biopharma (FRA:ET8) Cash From Discontinued Investi - GuruFocus.com

Oct 17, 2024

Oct 17, 2024

Cosciens Biopharma (FRA:ET8) Profitability Rank : 5 (As of Jun. 2024) - GuruFocus.com

Oct 17, 2024

Oct 17, 2024

Cosciens Biopharma (FRA:ET8) Shares Outstanding (EOP) : 3.06 Mil (As of Jun. 2024) - GuruFocus.com

Oct 17, 2024

Oct 17, 2024

Cosciens Biopharma (FRA:ET8) Free Cash Flow : €-5.76 Mil (TTM As of Jun. 2024) - GuruFocus.com

Oct 17, 2024

Oct 17, 2024

Cosciens Biopharma (FRA:ET8) Long-Term Debt & Capital Lease Obligation : €1.19 Mil (As of Jun. 2024) - GuruFocus.com

Oct 17, 2024

Oct 16, 2024

Cosciens Biopharma (FRA:ET8) Inventory-to-Revenue : 1.40 (As of Jun. 2024) - GuruFocus.com

Oct 16, 2024

Oct 16, 2024

Cosciens Biopharma (FRA:ET8) 3-Year Revenue Growth Rate : -13.80% (As of Jun. 2024) - GuruFocus.com

Oct 16, 2024

Oct 16, 2024

Cosciens Biopharma (FRA:ET8) Cyclically Adjusted PS Ratio : 0.56 (As of Oct. 16, 2024) - GuruFocus.com

Oct 16, 2024

Oct 10, 2024

The Escalator: Syneos Health, The FDA, Pfizer and more - MM+M Online

Oct 10, 2024

Oct 09, 2024

COSCIENS Biopharma streamlines board with resignation By Investing.com - Investing.com Canada

Oct 09, 2024

Oct 08, 2024

COSCIENS Biopharma reshuffles board of directors By Investing.com - Investing.com South Africa

Oct 08, 2024

Oct 08, 2024

COSCIENS Biopharma streamlines board with resignation - Investing.com

Oct 08, 2024

Oct 08, 2024

COSCIENS Biopharma reshuffles board of directors - Investing.com India

Oct 08, 2024

Oct 08, 2024

Cosciens Biopharma director Carolyn Egbert resigns - TipRanks

Oct 08, 2024

Oct 08, 2024

COSCIENS Biopharma Restructures Board After Resignation - TipRanks

Oct 08, 2024

Oct 08, 2024

COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewswire

Oct 08, 2024

Oct 02, 2024

AgEagle Aerial Systems Inc. Announces Closing of $6.5 Million Public Offering - The Manila Times

Oct 02, 2024

Oct 02, 2024

COSCIENS Biopharma names new board director By Investing.com - Investing.com South Africa

Oct 02, 2024

Oct 01, 2024

COSCIENS Biopharma names new board director - Investing.com

Oct 01, 2024

Oct 01, 2024

COSCIENS Biopharma Welcomes New Board Director - TipRanks

Oct 01, 2024